Literature DB >> 10491404

Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.

H Onda1, A Lueck, P W Marks, H B Warren, D J Kwiatkowski.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant genetic disorder in which benign hamartomas develop in multiple organs, caused by mutations in either TSC1 or TSC2. We developed a murine model of Tsc2 disease using a gene targeting approach. Tsc2-null embryos die at embryonic days 9.5-12.5 from hepatic hypoplasia. Tsc2 heterozygotes display 100% incidence of multiple bilateral renal cystadenomas, 50% incidence of liver hemangiomas, and 32% incidence of lung adenomas by 15 months of age. Progression to renal carcinoma, fatal bleeding from the liver hemangiomas, and extremity angiosarcomas all occur at a rate of less than 10%. The renal cystadenomas develop from intercalated cells of the cortical collecting duct and uniformly express gelsolin at high levels, enabling detection of early neoplastic lesions. The tumor expression pattern of the mice is influenced by genetic background, with fewer large renal cystadenomas in the outbred Black Swiss background and more angiosarcomas in 129/SvJae chimeric mice. The slow growth of the tumors in the heterozygote mice matches the limited growth potential of the great majority of TSC hamartomas, and the influence of genetic background on phenotype correlates with the marked variability in expression of TSC seen in patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491404      PMCID: PMC408440          DOI: 10.1172/JCI7319

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis.

Authors:  G H Xiao; F Shoarinejad; F Jin; E A Golemis; R S Yeung
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

2.  Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.

Authors:  M van Slegtenhorst; M Nellist; B Nagelkerken; J Cheadle; R Snell; A van den Ouweland; A Reuser; J Sampson; D Halley; P van der Sluijs
Journal:  Hum Mol Genet       Date:  1998-06       Impact factor: 6.150

3.  Gelsolin is a downstream effector of rac for fibroblast motility.

Authors:  T Azuma; W Witke; T P Stossel; J H Hartwig; D J Kwiatkowski
Journal:  EMBO J       Date:  1998-03-02       Impact factor: 11.598

4.  Widespread loss of gelsolin in breast cancers of humans, mice, and rats.

Authors:  H L Asch; K Head; Y Dong; F Natoli; J S Winston; J L Connolly; B B Asch
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

5.  Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors.

Authors:  E P Henske; L L Wessner; J Golden; B W Scheithauer; A O Vortmeyer; Z Zhuang; A J Klein-Szanto; D J Kwiatkowski; R S Yeung
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

6.  Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers.

Authors:  H Dosaka-Akita; F Hommura; H Fujita; I Kinoshita; M Nishi; T Morikawa; H Katoh; Y Kawakami; N Kuzumaki
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

7.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

Authors:  M van Slegtenhorst; R de Hoogt; C Hermans; M Nellist; B Janssen; S Verhoef; D Lindhout; A van den Ouweland; D Halley; J Young; M Burley; S Jeremiah; K Woodward; J Nahmias; M Fox; R Ekong; J Osborne; J Wolfe; S Povey; R G Snell; J P Cheadle; A C Jones; M Tachataki; D Ravine; J R Sampson; M P Reeve; P Richardson; F Wilmer; C Munro; T L Hawkins; T Sepp; J B Ali; S Ward; A J Green; J R Yates; J Kwiatkowska; E P Henske; M P Short; J H Haines; S Jozwiak; D J Kwiatkowski
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

8.  Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis.

Authors:  R S Yeung; C D Katsetos; A Klein-Szanto
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

9.  Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.

Authors:  E P Henske; B W Scheithauer; M P Short; R Wollmann; J Nahmias; N Hornigold; M van Slegtenhorst; C T Welsh; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

10.  Presence of potent transcriptional activation domains in the predisposing tuberous sclerosis (Tsc2) gene product of the Eker rat model.

Authors:  H Tsuchiya; K Orimoto; K Kobayashi; O Hino
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

View more
  155 in total

1.  Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism.

Authors:  David M Young; A Katrin Schenk; Shi-Bing Yang; Yuh Nung Jan; Lily Yeh Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Epileptogenesis in the Dysplastic Brain: A Revival of Familiar Themes.

Authors:  Scott C. Baraban
Journal:  Epilepsy Curr       Date:  2001-09       Impact factor: 7.500

3.  Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice.

Authors:  D Ehninger; Y Sano; P J de Vries; K Dies; D Franz; D H Geschwind; M Kaur; Y-S Lee; W Li; J K Lowe; J A Nakagawa; M Sahin; K Smith; V Whittemore; A J Silva
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

Review 4.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

5.  A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.

Authors:  T Kobayashi; O Minowa; Y Sugitani; S Takai; H Mitani; E Kobayashi; T Noda; O Hino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

6.  Computational Systems Bioinformatics and Bioimaging for Pathway Analysis and Drug Screening.

Authors:  Xiaobo Zhou; Stephen T C Wong
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2008-08-01       Impact factor: 10.961

7.  Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Authors:  Dan Ehninger; Sangyeul Han; Carrie Shilyansky; Yu Zhou; Weidong Li; David J Kwiatkowski; Vijaya Ramesh; Alcino J Silva
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 8.  Tuberous sclerosis complex: a brave new world?

Authors:  Kevin C Ess
Journal:  Curr Opin Neurol       Date:  2010-04       Impact factor: 5.710

9.  mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.

Authors:  Antonella Caccamo; Andrea Magrì; David X Medina; Elena V Wisely; Manuel F López-Aranda; Alcino J Silva; Salvatore Oddo
Journal:  Aging Cell       Date:  2013-03-24       Impact factor: 9.304

10.  Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Authors:  Jingxiang Huang; Shulin Wu; Chin-Lee Wu; Brendan D Manning
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.